Belgium Medical Inc. to Attend Porter Adventist Hospital Healthcare Conference & CARDEO Conference, Denver, Colorado September 17-19, 2004

VANCOUVER, BRITISH COLUMBIA, Sep 16, 2004 (CCNMatthews via COMTEX) --

Meridian Co., Ltd. ("Meridian") (OTC BB: MRDAF), is pleased to announce that its subsidiary, Belgium Medical Inc. ("MMI" or "the Company") will be attending the Porter Adventist Hospital Healthcare Conference & CARDEO Conference in Denver Colorado from September 17 - 19, 2004, at exhibitor booth numbers 708 and 834.

MMI is enthusiastic to introduce the Digital Pulse Analyzer ("DPA") to the preventative cardiology audience. MMI expects the attendees to be very receptive to the easy to use, FDA approved cardiovascular diagnostic device.

More About CARDEO: CARDEO'S Mission: Prevention before Intervention(TM)

Approximately 500 Primary Care Physicians, Cardiologists and Allied Healthcare professionals from across the United States will be attending this conference. The Consumer Health Expo will be open to the public on September 18th & 19th, 2004, and is expected to draw thousands of consumers of all ages and backgrounds.

CARDEO'S mission is to empower consumers, primary care physicians, healthcare providers, nutriceutical and pharmaceutical companies to launch a collaborative commitment to reduce and ultimately eliminate the nation's number one killer - heart disease. CARDEO strives to eradicate heart disease by increasing public awareness of heart attack risk factors, and encouraging broad public access to heart risk testing, early diagnosis, and preventative measures.

Porter Adventist Hospital will be hosting the Healthcare Conference that will take place prior to the CARDEO Consumer Health Expo.

More About: Digital Pulse Analyzer ("DPA")

The "DPA" accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA approved device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.

The Company feels that use of the "DPA" can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the #1 killer in the United States with an estimated economic cost of approximately $298 billion.

ABOUT MERIDIAN

Meridian is an established leader in the research/development, manufacturing, and sales of integrative medical diagnostic equipment. The company sells its products and equipment to a wide array of customers in the global health care industry. The company presently holds a total of 18 worldwide patents on its technology, and has received FDA, as well as other international regulatory approvals for many of its products.

Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.

Website (Korean): www.meridian.co.kr

Website (North America): meridianmedical.ca

Lexington Communications
Larry Kristof
1-877-899-4550
Email: 
[email protected]